메뉴 건너뛰기




Volumn 108, Issue 4, 2013, Pages 762-765

A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies

Author keywords

Bayesian; bortezomib; EWOC; Phase 1; sunitinib

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BORTEZOMIB; SUNITINIB;

EID: 84875216077     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.604     Document Type: Article
Times cited : (21)

References (15)
  • 1
    • 0031920799 scopus 로고    scopus 로고
    • Cancer phase i clinical trials: Efficient dose escalation with overdose control
    • Babb J, Rogatko A, Zacks S (1998) 'Cancer phase I clinical trials: efficient dose escalation with overdose control'. Stat Med 17(10): 1103-1120.
    • (1998) Stat Med , vol.17 , Issue.10 , pp. 1103-1120
    • Babb, J.1    Rogatko, A.2    Zacks, S.3
  • 3
    • 26844452967 scopus 로고    scopus 로고
    • Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
    • Boccadoro M, Morgan G, Cavenagh J (2005) 'Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy'. Cancer Cell Int 5(1): 18.
    • (2005) Cancer Cell Int , vol.5 , Issue.1 , pp. 18
    • Boccadoro, M.1    Morgan, G.2    Cavenagh, J.3
  • 4
    • 78049462514 scopus 로고    scopus 로고
    • Phase II study of daily sunitinib in FDG-PETpositive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation
    • Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG (2010) 'Phase II study of daily sunitinib in FDG-PETpositive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation'. Clin Cancer Res 16(21): 5260-5268.
    • (2010) Clin Cancer Res , vol.16 , Issue.21 , pp. 5260-5268
    • Carr, L.L.1    Mankoff, D.A.2    Goulart, B.H.3    Eaton, K.D.4    Capell, P.T.5    Kell, E.M.6    Bauman, J.E.7    Martins, R.G.8
  • 7
    • 36749052895 scopus 로고    scopus 로고
    • Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
    • Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS (2007) 'Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy'. Proc Natl Acad Sci USA 104(43): 17069-17074.
    • (2007) Proc Natl Acad Sci USA , vol.104 , Issue.43 , pp. 17069-17074
    • Ebos, J.M.1    Lee, C.R.2    Christensen, J.G.3    Mutsaers, A.J.4    Kerbel, R.S.5
  • 10
    • 77649322923 scopus 로고    scopus 로고
    • Safety and efficacy of combining sunitinib with bevacizumabpaclitaxel/ carboplatin in non-small cell lung cancer
    • Socinski MA, Scappaticci FA, Samant M, Kolb MM, Kozloff MF (2010) 'Safety and efficacy of combining sunitinib with bevacizumabpaclitaxel/carboplatin in non-small cell lung cancer'. J Thorac Oncol 5(3): 354-360.
    • (2010) J Thorac Oncol , vol.5 , Issue.3 , pp. 354-360
    • Socinski, M.A.1    Scappaticci, F.A.2    Samant, M.3    Kolb, M.M.4    Kozloff, M.F.5
  • 12
    • 78650229308 scopus 로고    scopus 로고
    • Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
    • Tighiouart M, Rogatko A (2010) 'Dose finding with escalation with overdose control (EWOC) in cancer clinical trials'. Stat Sci 25: 217-226.
    • (2010) Stat Sci , vol.25 , pp. 217-226
    • Tighiouart, M.1    Rogatko, A.2
  • 13
    • 0642349188 scopus 로고    scopus 로고
    • Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts
    • Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ (2003) 'Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts'. Mol Cancer Ther 2(9): 835-843.
    • (2003) Mol Cancer Ther , vol.2 , Issue.9 , pp. 835-843
    • Williams, S.1    Pettaway, C.2    Song, R.3    Papandreou, C.4    Logothetis, C.5    McConkey, D.J.6
  • 14
    • 77955729630 scopus 로고    scopus 로고
    • Combination therapy of bortezomib with novel targeted agents: An emerging treatment strategy
    • Wright JJ (2010) 'Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy'. Clin Cancer Res 16(16): 4094-4104.
    • (2010) Clin Cancer Res , vol.16 , Issue.16 , pp. 4094-4104
    • Wright, J.J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.